Anetumab（Cat No.:I042239）is a monoclonal antibody being investigated for the treatment of cancer, specifically targeting mesothelin, a protein overexpressed in several types of tumors, including ovarian, pancreatic, and mesothelioma. By binding to mesothelin, Anetumab may help to selectively deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. It is being explored as a targeted therapy for cancers where mesothelin is a key factor in tumor growth and progression. Clinical trials are ongoing to assess its safety, efficacy, and potential as part of combination therapies for cancer treatment.
